… ProQR Announces Axiomer® RNAEditing Licensing and Research Collaboration with Lilly … to up to five targets u sing ProQR’s proprietary Axiomer ® RNAediting platform ProQR to receive $ 5 0 million …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a … its clinical stage pipeline programs and the Axiomer ® RNAediting platform. ProQR leadership will highlight key …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that … RNA therapies for genetic eye diseases and our proprietary RNA-editing platform technology.” “I first met Daniel more than a …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3